SCHEMBL5477575

SCHEMBL5477575

Cc1ccccc1/C=C1\C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.76
▸ KMT2A Q03164 2/20 0.76
▸ LRRK2 Q5S007 4/20 0.67
▸ RET P07949 1/20 0.63
▸ PDGFRB P09619 1/20 0.59
▸ MDM2 Q00987 4/20 0.58
▸ RPS6KA3 P51812 1/20 0.57
▸ PSEN1 P49768 1/20 0.56
▸ PSEN2 P49810 1/20 0.56
▸ APH1B Q8WW43 1/20 0.56
▸ NCSTN Q92542 1/20 0.56
▸ APH1A Q96BI3 1/20 0.56
▸ PSENEN Q9NZ42 1/20 0.56
▸ IDO1 P14902 1/20 0.56
▸ TDO2 P48775 1/20 0.56
▸ TGM2 P21980 1/20 0.56
▸ FLT3 P36888 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5477578 1.00 MEN1 (0.76) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL13595188 0.89 MEN1 (0.64) MEN1KMT2ALRRK2RETMDM2
SCHEMBL5469641 0.86 LRRK2 (0.70) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL5469637 0.86 LRRK2 (0.70) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL17179651 0.86 MEN1 (1.00) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL14675111 0.84 MEN1 (1.00) MEN1KMT2AMDM2RPS6KA3FLT3
SCHEMBL14674713 0.84 NPC1 (0.70) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL5472890 0.84 PLK4 (0.70) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL14674712 0.84 NPC1 (0.70) MEN1KMT2ALRRK2RETPDGFRB
SCHEMBL14675110 0.84 MEN1 (1.00) MEN1KMT2AMDM2RPS6KA3FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 — — US claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 MEN1 1603/4885KMT2A 1891/4885LRRK2 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback